Bone Biologics 3Q 2026: Net Loss $618K, Diluted Loss per Share $0.17— 10-Q Summary

What happened

Bone Biologics reported a third-quarter 2026 net loss of $618K, narrower than its $667K loss a year earlier. Diluted loss per share was $0.17 versus $0.37. It continues developing its NELL-1 bone graft program.

Confirmed

Global impact / market context

A smaller loss means the company spent less money than it brought in relative to last year, stretching its cash further. Management says available cash should fund operations through the second quarter of 2027, giving limited time to reach key development milestones.

Analyst inference

Quarterly research and development spending rose 29% as the company extended NELL-1 protein shelf life and prepared for a future pivotal study. Rising spending alongside a narrower overall loss suggests cost cuts elsewhere offset higher development costs, a balance investors will watch.

Analyst inference

What to watch

1. The Australian pilot study of NB1, a NELL-1/DBM bone graft, is enrolling up to 30 spinal-fusion patients across six hospital sites. It assesses safety, bone fusion, pain, function and adverse events. Confirmed
2. Management expects continued substantial investment in NELL-1 development and says available cash is expected to fund operations through the second quarter of 2027, so investors should watch whether spending stays within that runway. Proposed
3. Because the FDA has indicated NELL-1/DBM is a combination product requiring PMA approval, a costly and lengthy process, investors should watch for trial data and regulatory progress before U.S. commercialization is possible. Analyst inference

Evidence

• Original source link unavailable